1 |
20 mg |
- |
- |
- |
- |
097 1件: 97 💬 |
2 |
20 mg bid of pf-02545920 |
- |
- |
- |
- |
008 1件: 8 💬 |
3 |
20 mg fampridine-sr (4-aminopyridine, 4-ap) |
Dalfampridine |
1件: D04127 D04127 💬 |
KCNA4 4件: KCNA4, KCNC3, KCND2, KCND3 💬 |
Cortisol synthesis and secretion 4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia |
013 1件: 13 💬 |
4 |
20 mg ga |
- |
- |
- |
- |
013 1件: 13 💬 |
5 |
20 mg mitoq |
- |
- |
- |
- |
013 1件: 13 💬 |
6 |
20 mg sildenafil citrate by mouth |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
7 |
Acomplia 20 mg film-coated tablets |
- |
- |
- |
- |
193 1件: 193 💬 |
8 |
Adcirca 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
9 |
Apremilast 20 mg |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
046 1件: 46 💬 |
10 |
Apremilast tablet 20 mg |
Apremilast |
1件: D08860 D08860 💬 |
PDE4A 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 |
Metabolic pathways 5件: Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway |
271 1件: 271 💬 |
11 |
Arava 20 mg filmdrasjerte tabletter |
- |
- |
- |
- |
046 1件: 46 💬 |
12 |
Arava 20 mg tablets (aventis pharmaceutical, inc.) |
- |
- |
- |
- |
046 1件: 46 💬 |
13 |
Arc1905 20 mg/ml |
- |
- |
- |
- |
301 1件: 301 💬 |
14 |
Atorvastatin tablet 20 mg |
Atorvastatin |
3件: D00258 D00258, D00887 D00887, D07474 D07474 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
046 1件: 46 💬 |
15 |
Azd9567 20 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
16 |
Baclofen 20 mg |
Baclofen |
1件: D00241 D00241 💬 |
GABBR1 2件: GABBR1, GABBR2 💬 |
Estrogen signaling pathway 7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
013 1件: 13 💬 |
17 |
Baclofen er capsules (grs) 20 mg |
Baclofen |
1件: D00241 D00241 💬 |
GABBR1 2件: GABBR1, GABBR2 💬 |
Estrogen signaling pathway 7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
013 1件: 13 💬 |
18 |
Bardoxolone methyl 20 mg |
Bardoxolone |
2件: D09584 D09584, D09585 D09585 💬 |
- |
- |
067 1件: 67 💬 |
19 |
Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour udca therapy |
Bezafibrate |
2件: D00734 D00734, D01366 D01366 💬 |
NR1H4 2件: NR1H4, PPARA 💬 |
Adipocytokine signaling pathway 9件: Adipocytokine signaling pathway, Bile secretion, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway |
094 1件: 94 💬 |
20 |
Bf 2.649 20 mg |
- |
- |
- |
- |
006 1件: 6 💬 |
21 |
Bibr 796 bs, 20 mg |
- |
- |
- |
- |
096 1件: 96 💬 |
22 |
Btt1023 iv infusion 20 mg/ml, 5 ml drug product |
- |
- |
- |
- |
094 1件: 94 💬 |
23 |
Carbidopa 20 mg |
Carbidopa |
1件: D00558 D00558 💬 |
DDC 1件: DDC 💬 |
Alcoholism 9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
006 1件: 6 💬 |
24 |
Chronocort® 20 mg |
- |
- |
- |
- |
081 1件: 81 💬 |
25 |
Cialis - 20 mg 2 compresse rivestite con film in blister uso orale |
- |
- |
- |
- |
075 1件: 75 💬 |
26 |
Cialis 20 mg comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
27 |
Cialis 20 mg film-coated tablets |
- |
- |
- |
- |
086 2件: 86, 113 💬 |
28 |
Copaxone - 20 mg/ml soluzione iniettabile in siringhe preriempite 30 siringhe |
- |
- |
- |
- |
013 1件: 13 💬 |
29 |
Copaxone 20 mg |
- |
- |
- |
- |
013 1件: 13 💬 |
30 |
Copaxone 20 mg/ml |
- |
- |
- |
- |
013 1件: 13 💬 |
31 |
Copaxone 20 mg/ml solución inyectable en jeringa precargada |
- |
- |
- |
- |
013 1件: 13 💬 |
32 |
Copaxone 20 mg/ml solución para inyección en jeringa precargada |
- |
- |
- |
- |
013 1件: 13 💬 |
33 |
Copaxone 20 mg/ml solution for injection, pre-filled syringe |
- |
- |
- |
- |
013 1件: 13 💬 |
34 |
Copaxone 20 mg/ml, solution for injection, pre-filled syringes |
- |
- |
- |
- |
013 1件: 13 💬 |
35 |
Cortancyl 20 mg |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
035 2件: 35, 162 💬 |
36 |
Cortancyl ® 20 mg |
Prednisone acetate |
1件: D08416 D08416 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
041 1件: 41 💬 |
37 |
Decortin 20 mg |
- |
- |
- |
- |
096 1件: 96 💬 |
38 |
Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg |
Dextromethorphan |
7件: D00642 D00642, D00643 D00643, D00848 D00848, D02272 D02272, D03742 D03742, D03744 D03744, D08458 D08458 💬 |
GRIN1 11件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SIGMAR1 💬 |
Adrenergic signaling in cardiomyocytes 22件: Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway |
002 2件: 2 , 13 💬 |
39 |
Doptelet 20 mg film-coated tablets |
- |
- |
- |
- |
063 1件: 63 💬 |
40 |
Duodopa, 20 mg/ml + 5 mg/ml, intestinal gel |
- |
- |
- |
- |
006 1件: 6 💬 |
41 |
Duodopa, levodopa 20 mg/ml + carbidopa 5 mg/ml, intestinal gel |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
42 |
Encapsulated baclofen 20 mg |
Baclofen |
1件: D00241 D00241 💬 |
GABBR1 2件: GABBR1, GABBR2 💬 |
Estrogen signaling pathway 7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
013 1件: 13 💬 |
43 |
Esomeprazole 20 mg |
Esomeprazole |
4件: D01984 D01984, D04056 D04056, D07917 D07917, D09339 D09339 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
046 1件: 46 💬 |
44 |
Famotidine 20 mg |
Famotidine |
1件: D00318 D00318 💬 |
HRH2 1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
086 1件: 86 💬 |
45 |
Ga 20 mg/ml |
- |
- |
- |
- |
013 1件: 13 💬 |
46 |
Glatiramer acetate 20 mg |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
47 |
Glatiramer acetate 20 mg, with mitoxantrone |
Acetate |
3件: D02166 D02166, D04318 D04318, D08224 D08224 💬 |
HLA-A 22件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 |
Allograft rejection 33件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
48 |
Glatiramer acetate 20 mg/0.5 ml |
Acetate |
1件: D04318 D04318 💬 |
HLA-A 20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 |
Allograft rejection 32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
49 |
Gwp42003-p 20 mg/kg/day dose |
- |
- |
- |
- |
140 2件: 140, 144 💬 |
50 |
Humira 20 mg solution for injection in pre-filled syringe |
- |
- |
- |
- |
096 1件: 96 💬 |
51 |
Infliximab 20 mg/kg |
Infliximab |
1件: D02598 D02598 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
096 1件: 96 💬 |
52 |
Ipx056 20 mg |
- |
- |
- |
- |
013 1件: 13 💬 |
53 |
Ipx056-20 mg |
- |
- |
- |
- |
013 1件: 13 💬 |
54 |
Isosorbide dinitrate 20 mg |
Isosorbide |
2件: D00347 D00347, D00516 D00516 💬 |
- |
- |
113 1件: 113 💬 |
55 |
Istradefylline 20 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
56 |
Istradefylline 20 mg or 40 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
57 |
Lci699, 20 mg |
- |
- |
- |
- |
075 1件: 75 💬 |
58 |
Leflunomide 20 mg tablets (geneva pharmaceutical) |
Leflunomide |
1件: D00749 D00749 💬 |
DHODH 1件: DHODH 💬 |
Biosynthesis of cofactors 3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism |
046 1件: 46 💬 |
59 |
Leflunomide 20 mg+prednisone 0.5mg/kg/d |
Leflunomide |
2件: D00473 D00473, D00749 D00749 💬 |
DHODH 2件: DHODH, NR3C1 💬 |
Biosynthesis of cofactors 4件: Biosynthesis of cofactors, Metabolic pathways, Neuroactive ligand-receptor interaction, Pyrimidine metabolism |
066 1件: 66 💬 |
60 |
Lenabasum 20 mg |
- |
- |
- |
- |
050 3件: 50, 51, 299 💬 |
61 |
Lenabasum 20 mg powder in capsule |
- |
- |
- |
- |
051 1件: 51 💬 |
62 |
Lojuxta 20 mg hard capsules |
- |
- |
- |
- |
079 1件: 79 💬 |
63 |
Losec capsules 20 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
64 |
Ly3337641 20 mg |
- |
- |
- |
- |
046 1件: 46 💬 |
65 |
Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d |
Melarsoprol |
2件: D00832 D00832, D00833 D00833 💬 |
- |
- |
065 1件: 65 💬 |
66 |
Methylphenidate modified release 20 mg |
Methylphenidate |
2件: D01296 D01296, D04999 D04999 💬 |
SLC6A2 2件: SLC6A2, SLC6A3 💬 |
Alcoholism 7件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Synaptic vesicle cycle |
013 1件: 13 💬 |
67 |
Mozobil - 20 mg/ml - soluzione iniettabile - uso sottocutaneo - f |
- |
- |
- |
- |
019 1件: 19 💬 |
68 |
Mozobil - 20 mg/ml - soluzione iniettabile - uso sottocutaneo - flaconcino (vetro) - 24 mg/1.2 ml 1 flaconcino |
- |
- |
- |
- |
065 1件: 65 💬 |
69 |
Mysildecard 20 mg |
- |
- |
- |
- |
210 1件: 210 💬 |
70 |
Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d |
Eflornithine |
2件: D00833 D00833, D07883 D07883 💬 |
ODC1 1件: ODC1 💬 |
Arginine and proline metabolism 3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways |
065 1件: 65 💬 |
71 |
Omaveloxolone capsules, 20 mg |
Omaveloxolone |
1件: D10964 D10964 💬 |
NFE2L2 1件: NFE2L2 💬 |
Fluid shear stress and atherosclerosis 5件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum |
018 1件: 18 💬 |
72 |
Omeprazole 20 mg |
Omeprazole |
4件: D00455 D00455, D01207 D01207, D05259 D05259, D05261 D05261 💬 |
ATP4A 2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
096 2件: 96, 97 💬 |
73 |
Oxn 20 mg / 10 mg pr |
- |
- |
- |
- |
006 1件: 6 💬 |
74 |
Oxycodone/naloxone prolonged release tablets 20 mg /10 mg |
Naloxone |
5件: D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 3件: OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway 5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
75 |
Pantoprazolo 20 mg gastro-resistant tablets |
- |
- |
- |
- |
065 1件: 65 💬 |
76 |
Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp |
Paroxetine |
12件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 2件: NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 1件: 46 💬 |
77 |
Paroxetine hydrochloride tablets 10 & 20 mg and prednisolone 1 mg bp |
Paroxetine |
12件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D02260 D02260, D02362 D02362, D03301 D03301, D05374 D05374, D05375 D05375 💬 |
NR3C1 2件: NR3C1, SLC6A4 💬 |
Neuroactive ligand-receptor interaction 3件: Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle |
046 1件: 46 💬 |
78 |
Pf-06650833 20 mg |
PF-06650833 |
- |
- |
- |
046 1件: 46 💬 |
79 |
Plenadren 20 mg modified-release tablets |
- |
- |
- |
- |
078 1件: 78 💬 |
80 |
Plovamer acetate 20 mg |
Acetate |
- |
- |
- |
013 1件: 13 💬 |
81 |
Pn 200 tablets (500 mg naproxen and 20 mg omeprazole) |
Naproxen |
5件: D00118 D00118, D00455 D00455, D01207 D01207, D05259 D05259, D05261 D05261 💬 |
ATP4A 4件: ATP4A, ATP4B, PTGS1, PTGS2 💬 |
Alzheimer disease 26件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Collecting duct acid secretion, Gastric acid secretion, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxidative phosphorylation, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 2件: 46, 271 💬 |
82 |
Ponesimod 20 mg |
Ponesimod |
1件: D11215 D11215 💬 |
S1PR1 1件: S1PR1 💬 |
FoxO signaling pathway 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
013 1件: 13 💬 |
83 |
Prednisolone 20 mg |
Prednisolone |
8件: D00472 D00472, D00980 D00980, D00981 D00981, D00982 D00982, D01239 D01239, D01998 D01998, D02156 D02156, D03301 D03301 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
84 |
Prednison acis® 20 mg |
- |
- |
- |
- |
043 2件: 43, 44 💬 |
85 |
Revatio 20 mg |
- |
- |
- |
- |
085 1件: 85 💬 |
86 |
Revatio 20 mg film coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
87 |
Revatio 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
88 |
Revatio 20 mg filmtabletten |
- |
- |
- |
- |
086 1件: 86 💬 |
89 |
Revatio 20 mg, comprimidos recubiertos con película |
- |
- |
- |
- |
086 1件: 86 💬 |
90 |
Revatio ® 20 mg film-coated tablets |
- |
- |
- |
- |
086 1件: 86 💬 |
91 |
Rivaroxaban 20 mg |
Rivaroxaban |
1件: D07086 D07086 💬 |
F10 1件: F10 💬 |
Complement and coagulation cascades 1件: Complement and coagulation cascades |
091 1件: 91 💬 |
92 |
Roactemra 20 mg/ml concentrado para solución para perfusión |
- |
- |
- |
- |
046 1件: 46 💬 |
93 |
Roactemra 20 mg/ml concentrate for solution for infusion |
- |
- |
- |
- |
046 1件: 46 💬 |
94 |
Roactemra 20 mg/ml concentrate for solution for infusion. |
- |
- |
- |
- |
046 1件: 46 💬 |
95 |
Roactemra 20 mg/ml, concentrado para solución para perfusión |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
96 |
Sandostatin lar 20 mg |
- |
- |
- |
- |
227 1件: 227 💬 |
97 |
Sandostatina - lar 20 mg/2.5 ml polvere e solvente per sospensione iniettabile flacone polvere + siringa preriempita 2.5 ml + 2 aghi |
- |
- |
- |
- |
067 1件: 67 💬 |
98 |
Sildenafil (revatio) 20 mg tid |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
99 |
Sildenafil 20 mg tablets |
Sildenafil |
2件: D02229 D02229, D08514 D08514 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
278 1件: 278 💬 |
100 |
Simvastatin 20 mg |
Simvastatin |
1件: D00434 D00434 💬 |
HMGCR 1件: HMGCR 💬 |
AMPK signaling pathway 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
046 1件: 46 💬 |
101 |
Som230 lar, 20 mg |
- |
- |
- |
- |
075 1件: 75 💬 |
102 |
Tadalafil 20 mg |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
113 1件: 113 💬 |
103 |
Tadalafil 20 mg film-coated tablets |
Tadalafil |
1件: D02008 D02008 💬 |
PDE5A 1件: PDE5A 💬 |
Metabolic pathways 3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
104 |
Tafamidis meglumine 20 mg soft gelatin capsules |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
105 |
Targinact 20 mg/10 mg prolonged-release tablets |
- |
- |
- |
- |
006 1件: 6 💬 |
106 |
Tpi-287 20 mg/m2 |
- |
- |
- |
- |
005 2件: 5 , 7 💬 |
107 |
Zx008 - 20 mg/day maximum dose |
- |
- |
- |
- |
140 1件: 140 💬 |